L-Arginine/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment

被引:1
|
作者
Sinningen, Kathrin [1 ]
Emons, Barbara [2 ,3 ]
Boehme, Pierre [3 ]
Juckel, Georg [2 ,3 ]
Hanusch, Beatrice [1 ]
Beckmann, Bibiana [4 ]
Tsikas, Dimitrios [4 ]
Luecke, Thomas [1 ]
机构
[1] Ruhr Univ Bochum, Univ Childrens Hosp, D-44791 Bochum, Germany
[2] Ruhr Univ Bochum, LWL Univ Hosp, LWL Inst Mental Hlth, Dept Psychiat, D-44791 Bochum, Germany
[3] Ruhr Univ Bochum, LWL Univ Hosp, Dept Psychiat, D-44791 Bochum, Germany
[4] Hannover Med Sch, Inst Toxicol, Core Unit Prote, D-30623 Hannover, Germany
来源
关键词
ADHD; Neurodevelopmental disorder; Nitric oxide; Stimulant; Methylphenidate; Neurodivergent; Pediatric; Adult medicine; DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; NITRIC-OXIDE; NITRATE; PLASMA; PREVALENCE; CHILDREN; HEALTH;
D O I
10.1016/j.niox.2023.06.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Attention deficit hyperactivity disorder (ADHD) is a mental disorder that was once thought to occur only in children. Meanwhile, it is known that adults can also be affected. The first-line drug in children and adults to treat symptoms of inattention, impulsivity, lack of self-regulation, and hyperactivity is methylphenidate (MPH). Known adverse effects of MPH include cardiovascular problems, such as elevated blood pressure and heart rate. Therefore, biomarkers to monitor potential cardiovascular side effects of MPH are needed. The L- Arginine/Nitric oxide (Arg/NO) pathway is involved in noradrenaline and dopamine release as well as in normal cardiovascular functioning and is therefore a prime candidate for the search of biomarkers. The aim of the present study was to investigate the Arg/NO pathway as well as oxidative stress in adult ADHD patients in plasma and urine and the potential influence of MPH medication.Methods: In plasma and urine samples of 29 adults with ADHD (39.2 & PLUSMN; 10.9 years) and 32 healthy adults serving as controls (CO) (38.0 & PLUSMN; 11.6 years) the major NO metabolites nitrite and nitrate, Arg, the NO synthesis inhibitor asymmetric dimethylarginine (ADMA) and its major urinary metabolite dimethylamine (DMA) as well as malondialdehyde (MDA) were measured by gas chromatography-mass spectrometry.Results: Of the 29 patients with ADHD 14 were currently without MPH treatment (-MPH) and 15 were treated with MPH (+MPH). Plasma nitrate concentrations were significantly higher in patients not treated with MPH vs. CO (-MPH 60.3 & mu;M [46.2-76.0] vs. CO 44.4 & mu;M [35.0-52.7]; p = 0.002), while plasma nitrite tended to be higher in-MPH patients (2.77 & mu;M [2.26-3.27]) vs. CO (2.13 & mu;M [1.50-2.93]; p = 0.053). Additionally, plasma creat-inine concentrations were significantly different, with-MPH showing significantly higher concentrations than the other two groups (-MPH 141 & mu;M [128-159]; +MPH 96.2 & mu;M [70.2-140]; Co 75.9 & mu;M [62.0-94.7]; p < 0.001). Urinary creatinine excretion tended to be lowest in-MPH group vs. +MPH and CO (-MPH 11.4 & PLUSMN; 8.88 mM; +MPH 20.7 & PLUSMN; 9.82 mM; 16.6 & PLUSMN; 7.82 mM; p = 0.076). None of the other metabolites, including MDA, a marker of oxidative stress, showed a difference between the groups. Conclusion: Adult patients with ADHD, who are not treated with MPH (-MPH), showed varied Arg/NO pathway, but Arg bioavailability seemed to be consistent over the groups. Our findings imply that urinary reabsorption may be increase and/or excretion of nitrite and nitrate may be decreased in ADHD, resulting in an increase in the plasma concentration of nitrite. MPH seems to partially reverse these effects by not yet known mechanisms, and does not affect oxidative stress.
引用
收藏
页码:64 / 69
页数:6
相关论文
共 50 条
  • [21] THE ENDOTHELIAL L-ARGININE NITRIC-OXIDE PATHWAY AND THE RENAL CIRCULATION
    LUSCHER, TF
    BOCK, HA
    KLINISCHE WOCHENSCHRIFT, 1991, 69 (13): : 603 - 609
  • [22] AMELIORATION BY L-ARGININE OF A DYSFUNCTIONAL ARGININE NITRIC-OXIDE PATHWAY IN DIABETIC ENDOTHELIUM
    PIEPER, GM
    PELTIER, BA
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (03) : 397 - 403
  • [23] MANIPULATION OF THE L-ARGININE NITRIC-OXIDE PATHWAY IN EXPERIMENTAL COLITIS
    NEILLY, PJD
    KIRK, SJ
    GARDINER, KR
    ANDERSON, NH
    ROWLANDS, BJ
    BRITISH JOURNAL OF SURGERY, 1995, 82 (09) : 1188 - 1191
  • [24] Neuronal effects of L-arginine not associated with synthesis of nitric oxide
    D'yakonova T.L.
    Doklady Biological Sciences, 2005, 400 (1-6) : 16 - 21
  • [25] EFFECT OF L-ARGININE ON THYMIC FUNCTION - POSSIBLE ROLE OF L-ARGININE-NITRIC OXIDE (NO) PATHWAY
    MOCCHEGIANI, E
    NISTICO, G
    SANTARELLI, L
    FABRIS, N
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1994, : 163 - 170
  • [26] Altered L-arginine/nitric oxide synthase/nitric oxide pathway in the vascular adventitia of rats with sepsis
    Jia, Yue Xia
    Pan, Chun Shui
    Yang, Jing Hui
    Liu, Xiu Hua
    Yuan, Wen Jun
    Zhao, Jing
    Tang, Chao Shu
    Qi, Yong Fen
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (12) : 1202 - 1208
  • [27] POSSIBLE INVOLVEMENT OF THE L-ARGININE NITRIC-OXIDE PATHWAY IN THE MODULATION OF STRESS-INDUCED ANALGESIA
    HAULICA, I
    BUSUIOC, A
    NEAMTU, C
    DORNEANU, V
    TITU, G
    SPAC, A
    FUNCTIONAL NEUROLOGY, 1995, 10 (4-5) : 169 - 173
  • [28] L-arginine supplementation increases plasma L-arginine but does not increase plasma nitric oxide during mental stress
    Tyler, RC
    Coussons-Read, ME
    Oliver-Picket, C
    Tyler, AN
    Weil, JV
    FASEB JOURNAL, 2000, 14 (04): : A117 - A117
  • [29] Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: Role of nitric oxide.
    Samira, Saleh
    Ebtehal, El-Demerdash
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 59 - 59
  • [30] L-arginine, tetrahydrobiopterin, nitric oxide and diabetes
    Hoang, Hai H.
    Padgham, Samuel V.
    Meininger, Cynthia J.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2013, 16 (01): : 76 - 82